Gilead Sciences reaches settlement on Biktarvy patent litigation with generics
PositiveFinancial Markets
Gilead Sciences has successfully reached a settlement regarding the patent litigation surrounding its HIV medication, Biktarvy, with generic manufacturers. This agreement is significant as it allows for the continued availability of Biktarvy while ensuring that Gilead can protect its intellectual property. The resolution of this legal dispute not only benefits Gilead but also ensures that patients have access to effective treatment options without prolonged legal battles.
— Curated by the World Pulse Now AI Editorial System